[Latest] Global Cancer Supportive Care Drugs Market Size/Share Worth USD 32,783.2 Billion by 2033 at a 3.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 mai 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Supportive Care Drugs Market Size, Trends and Insights By Drug Type...
[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 mai 2024 08h30 HE
|
Custom Market Insights
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Therapeutics Market Size, Trends and Insights By Type of Therapy...
[Latest] Global Hereditary Cancer Testing Market Size/Share Worth USD 12.1 Billion by 2033 at a 7.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
02 avr. 2024 14h00 HE
|
Custom Market Insights
Austin, TX, USA, April 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hereditary Cancer Testing Market Size, Trends and Insights By Disease Type...
[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
28 mars 2024 15h30 HE
|
Custom Market Insights
Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trends and Insights By Type of Immunotherapy...
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 mars 2024 14h30 HE
|
Custom Market Insights
Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...
[Latest] Global Proton Therapy Market Size/Share Worth USD 2,405.6 Million by 2032 at a 12.11% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
07 mars 2024 11h30 HE
|
Custom Market Insights
Austin, TX, USA, March 07, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Proton Therapy Market Size, Trends and Insights By Setup Type (Single-Room...
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
13 févr. 2024 16h30 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
[Latest] Global Medical Implant Market Size/Share Worth USD 203.6 Billion by 2032 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
05 févr. 2024 23h30 HE
|
Custom Market Insights
Austin, TX, USA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Medical Implant Market Size, Trends and Insights By Product Type (Orthopedic...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
18 janv. 2024 17h00 HE
|
Axogen, Inc.
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 16h02 HE
|
Olema Oncology
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarterNew clinical data for palazestrant...